Filing Flows › Integra Lifesciences Holdings (IART) › Q3 2025
Integra Lifesciences Holdings (IART) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Integra Lifesciences Holdings (IART) reported revenue of $402M for the third quarter 2025 (Q3 2025), +6% from a year earlier and -3% from the quarter before. Operating margin was 2.9%, net loss $5.4M (1.3% of revenue).
Integra Lifesciences Holdings, Q3 2025: revenue $402M (+6% year over year), operating margin 2.9%, net loss $5.4M, operating cash flow $40.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $402M | -3% | +6% |
| Operating profit | $11.8M | — | — |
| Net earnings | −$5.4M | — | — |
| Operating cash flow | $40.9M | +359% | +82% |
| Free cash flow | $25.8M | — | — |
What changed
Revenue was $402.1M in Q3 2025, up 6% year over year and down 3% from the previous quarter. Codman Specialty Surgical was the largest line at 73% of revenue. Codman Specialty Surgical added $21.8M year over year (up 8%), 103% of the total change. Tissue Technologies declined 1%.
Operating profit was $11.8M, a 2.9% margin (up 5.1 points year over year). Total costs grew 0% against revenue growth of 6%. The quarter ended with a net loss of $5.4M, narrower than the previous quarter's $484.1M loss. Net interest and other expense of $18.6M was the main reason.
Operating cash flow was $40.9M (up 82% year over year). Non-cash charges added back $5.6M of share-based compensation. Working capital and other items added $40.7M. Capital expenditures of $15.2M left free cash flow of $25.8M.
Questions
What was Integra Lifesciences Holdings' revenue in the third quarter 2025?
Integra Lifesciences Holdings (IART) reported revenue of $402M for the third quarter 2025 (Q3 2025), +6% from a year earlier and -3% from the quarter before.
Was Integra Lifesciences Holdings profitable in the third quarter 2025?
Operating profit was $11.8M (2.9% of revenue) and net loss $5.4M.